Lower-dose transplant drug for older or frail patients with blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether a lower dose of a drug used after bone marrow transplant can reduce side effects while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). It is for older patients or those who are not healthy enough for a standard, stronger conditioning regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer that is in remission or under control, such as acute leukemia, myelodysplastic syndrome, lymphoma, or certain other blood disorders.
- You are between 60 and 85 years old, or between 18 and 60 with health issues that make a standard, stronger transplant prep unsafe.
- You have a suitable donor (related or unrelated, matched or partially matched).
- Your heart, lungs, kidneys, and liver function are above certain minimum levels.
- You are willing to use birth control if you or your partner can become pregnant, and not breastfeed during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Hear when a new Hematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.